The FDA is currently reviewing applications from Alkermes regarding the seeking of designation for the drug alixorexton for investigational use and narcolepsy.
1 report, 1 independent
Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is currently reviewing applications from Alkermes regarding the seeking of designation for the drug alixorexton for investigational use and narcolepsy.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- Ohio covers FDA-approved uses of drugs, supported by scientific basis from the National Institutes of Health.